Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2014', provides an overview of the Vertex Pharmaceuticals Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vertex Pharmaceuticals Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vertex Pharmaceuticals Incorporated including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Vertex Pharmaceuticals Incorporated's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vertex Pharmaceuticals Incorporated's pipeline products Reasons to buy - Evaluate Vertex Pharmaceuticals Incorporated's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vertex Pharmaceuticals Incorporated in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vertex Pharmaceuticals Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vertex Pharmaceuticals Incorporated and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vertex Pharmaceuticals Incorporated - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Vertex Pharmaceuticals Incorporated and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Vertex Pharmaceuticals Incorporated Snapshot 6 Vertex Pharmaceuticals Incorporated Overview 6 Key Information 6 Key Facts 6 Vertex Pharmaceuticals Incorporated - Research and Development Overview 7 Key Therapeutic Areas 7 Vertex Pharmaceuticals Incorporated - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 12 Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Vertex Pharmaceuticals Incorporated - Drug Profiles 18 telaprevir 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 lumacaftor 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 decernotinib 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 VX-135 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 VX-661 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 VX-787 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 VX-970 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 VE-465 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 VE-821 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 VE-822 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Next Generation Correctors 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule to Antagonize CGRP Receptor for Migraine 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules for Cancer 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules for Huntington Disease 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules for Multiple Sclerosis 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit Protein Kinase for Tuberculosis 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 VRT-325 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vertex Pharmaceuticals Incorporated - Pipeline Analysis 41 Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 41 Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 43 Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 44 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 45 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 47 Vertex Pharmaceuticals Incorporated - Dormant Projects 58 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 60 Discontinued Pipeline Product Profiles 60 ALS-2158 60 pralnacasan 60 VX-745 60 VX-759 60 VX-983 60 Vertex Pharmaceuticals Incorporated - Company Statement 61 Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 63 Head Office 63 Other Locations & Subsidiaries 63 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 66 Disclaimer 66
List of Tables Vertex Pharmaceuticals Incorporated, Key Information 6 Vertex Pharmaceuticals Incorporated, Key Facts 6 Vertex Pharmaceuticals Incorporated - Pipeline by Indication, 2014 9 Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2014 10 Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2014 11 Vertex Pharmaceuticals Incorporated - Pre-Registration, 2014 12 Vertex Pharmaceuticals Incorporated - Phase III, 2014 13 Vertex Pharmaceuticals Incorporated - Phase II, 2014 14 Vertex Pharmaceuticals Incorporated - Phase I, 2014 15 Vertex Pharmaceuticals Incorporated - Preclinical, 2014 16 Vertex Pharmaceuticals Incorporated - Discovery, 2014 17 Vertex Pharmaceuticals Incorporated - Pipeline by Target, 2014 42 Vertex Pharmaceuticals Incorporated - Pipeline by Route of Administration, 2014 43 Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2014 44 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action, 2014 46 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates, 2014 47 Vertex Pharmaceuticals Incorporated - Dormant Developmental Projects,2014 58 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2014 60 Vertex Pharmaceuticals Incorporated, Other Locations 63 Vertex Pharmaceuticals Incorporated, Subsidiaries 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
